Staphylococcus epidermidis biofilms control by N-acetylcysteine and rifampicin

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorLeite, Bruna
dc.creatorGomes, Fernanda
dc.creatorTeixeira, Pilar
dc.creatorSouza, Clovis
dc.creatorPizzolitto, Elisabeth
dc.creatorOliveira, Rosário
dc.date2014-05-27T11:29:49Z
dc.date2016-10-25T18:50:34Z
dc.date2014-05-27T11:29:49Z
dc.date2016-10-25T18:50:34Z
dc.date2013-07-01
dc.date.accessioned2017-04-06T02:28:56Z
dc.date.available2017-04-06T02:28:56Z
dc.identifierAmerican Journal of Therapeutics, v. 20, n. 4, p. 322-328, 2013.
dc.identifier1075-2765
dc.identifier1536-3686
dc.identifierhttp://hdl.handle.net/11449/75798
dc.identifierhttp://acervodigital.unesp.br/handle/11449/75798
dc.identifier10.1097/MJT.0b013e318209e17b
dc.identifierWOS:000321982100003
dc.identifier2-s2.0-84880778397
dc.identifierhttp://dx.doi.org/10.1097/MJT.0b013e318209e17b
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/896530
dc.descriptionMedical device-associated infections caused by Staphylococcus epidermidis usually involve biofilm formation and its eradication is particularly challenging. Although rifampicin has been proving to be one of the most effective antibiotics against S. epidermidis biofilms, its use as a single agent can lead to the acquisition of resistance. Therefore, we assessed the combined effect of rifampicin with N-acetylcysteine (NAC) known by its mucolytic effect, in the control of S. epidermidis biofilms. Biofilms of 2 S. epidermidis strains (9142 and 1457) were treated with 1× minimum inhibitory concentration (4 mg/mL) and 10× minimum inhibitory concentration (40 mg/mL) of NAC and 10 mg/L (peak serum) of rifampicin alone and in combination. NAC at 40 mg/L alone or in combination with rifampicin (10 mg/L) significantly reduced (4 log 10) the number of biofilm cells. Considering their different modes of action, the association of NAC with rifampicin constitutes a promising therapeutic strategy in the treatment of infections associated to S. epidermidis biofilms. © 2013 Lippincott Williams & Wilkins.
dc.languageeng
dc.relationAmerican Journal of Therapeutics
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBiofilm
dc.subjectN-acetylcysteine
dc.subjectPlanktonic cells
dc.subjectRifampicin
dc.subjectStaphylococcus epidermidis
dc.subjectacetylcysteine
dc.subjectmucolytic agent
dc.subjectrifampicin
dc.subjectbacterial strain
dc.subjectbiofilm
dc.subjectcontrolled study
dc.subjectdevice infection
dc.subjectdrug effect
dc.subjectminimum inhibitory concentration
dc.subjectmucolysis
dc.subjectnonhuman
dc.subjectpriority journal
dc.titleStaphylococcus epidermidis biofilms control by N-acetylcysteine and rifampicin
dc.typeOtro


Este ítem pertenece a la siguiente institución